Physicians' Academy for Cardiovascular Education

PCSK9, the short track road from discovery as drug target towards the clinic

10' education - Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

This lecture was part of a CME accredited symposium: PCSK9 inhibition in clinical lipid management: A critical review of evidence and opportunities held at ESC 2016 in Rome

Video navigation menu

  • The discovery of PCSK9 - a brief overview 00:14
  • Cardiovascular benefits of PCSK9 loss of function mutations 02:55
  • The biology of PCSK9 04:12
  • The development of PCSK9 inhibitors 08:34
  • PCSK9 inhibitors also reduce Lp(a) by increasing its hepatic secretion 09:43
  • Conclusion 12:36

Educational information

Educational objectives of this symposium were to:

CME accreditation

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Disclosures

Prof Gilles Lambert is Professor in Cell Biology and Biochemistry at the University of La Réunion Medical School (France) and a principal investigator at Inserm UMR1188 DéTROI.

Funding

Supported by unrestricted educational grants from Amgen, Pfizer, and Sanofi-Regeneron.

Also view lecture: A clinical perspective on PCSK9 inhibition: What do we know an what can we expect? , by Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston Also view lecture: Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?, by prof John Kastelein, MD – AMC, Amsterdam, The Netherlands

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.

Share this page with your colleagues and friends: